Elevation Oncology, Inc.

At a time when accessing capital has become increasingly difficult, leaving more and more biopharma firms to consider a range of less-than-stellar strategic alternatives, Alis Biosciences has emerged

Dozens of public biopharmaceutical companies have announced plans in 2025 to assess strategic alternatives after clinical trial setbacks or as cash stockpiles dwindled. Both ESSA Pharma and Elevation

Cargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’